瑞替普酶与尿激酶治疗急性心肌梗死疗效及安全性分析

郝晓勇

（陕西省延安市子长县人民医院心血管内一科，陕西 延安，717300）

浏览次数：245次 下载次数：335次

摘要：

目的 探讨瑞替普酶与尿激酶治疗急性心肌梗死的疗效及安全性。方法 选取2011年2月至2016年2月我院收治的急性心肌梗死患者120例作为研究对象，将其分为观察组与对照组，各60例。观察组患者采用瑞替普酶治疗，对照组患者采用尿激酶治疗，比较两组疗效及安全性。结果 观察组溶栓后30、60、90、120 min冠脉再通率显著高于对照组，差异有统计学 意义（P<0.05）。观察组患者的出血发生率显著低于对照组，差异有统计学意义（P<0.05）。两组患者其他并发症发生率比较差 异不显著（P>0.05）。结论 瑞替普酶治疗急性心肌梗死的疗效及安全性均优于尿激酶，值得临床推广应用。

关键词：急性心肌梗死；瑞替普酶；尿激酶

中图分类号：R542.22文献标志码：A文章编号：2096-1413(2016)25-0076-02

Clinical efficacy and safety analysis of reteplase and urokinase in treatment of acute myocardial infarction
HAO Xiao-yong
(1st Cardiovascular Medicine Department, Zichang County People`s Hospital of Shaanxi Province, Yan`an 717300, China)

ABSTRACT: Objective To explore the clinical efficacy and safety of reteplase and urokinase in the treatment of acute myocardial infarction. Methods One hundred and twenty patients with acute myocardial infarction accepted in our hospital from February 2011 to February 2016 were selected and divided into observation group and control group, with 60 cases in each group. Patients in the observation group were given reteplase, patients in the control group were given urokinase. Then the clinical efficacy and safety of two groups were observed and compared. Results The rates of reperfusion 30, 60, 90 min and 120 min after thrombolytic therapy were obviously higher than those of control group with statistical significance (P<0.05). The bleeding rate of observation group was obvioulsy lower than those of the control group with statistical significance (P<0.05). Other complications of two groups had no statistical difference (P>0.05). Conclusion Reteplase has a better efficacy and safety compared to urokinase in treatment of acute myocardial infarction, which is worth of clinical application.

KEYWORDS: acute myocardial infarction; reteplase; urokinase

参考文献：
[1] 李淑坤,莫晓聪,季钰尧,等.48 例急性心肌梗死的临床诊断和治疗 体会[J].中国现代药物应用,2016,10(5):178-179.
[2] 杨玉强.早期尿激酶静脉溶栓救治急性心肌梗死的临床价值[J].中 国实用医刊,2016,43(3):42-43.
[3] 王彩云.阿替普酶静脉溶栓治疗急性心肌梗死疗效观察[J].世界最 新医学信息文摘:连续型电子期刊,2016,16(34):95,98.
[4] 易远明.氯吡格雷联用辛伐他汀对急性心肌梗死再发的预防[J].中 国老年学杂志,2013,33(9):2018-2020.
[5] 姚朱华,陈湾湾,曹明英,等.注射用重组人尿激酶原治疗急性ST 段 抬高型心肌梗死的疗效和安全性及影响因素分析[J].中国全科医学,2016,19(9):1061-1066.
[6] 李硕,靳温,李成华,等.心肌梗死与颈动脉血流动力学及同型半胱 氨酸血症的关系[J].遵义医学院学报,2015,38(6):615-617,621.
[7] 周发展,武君,张春玲,等.替罗非班应用于急诊经皮冠状动脉介入 治疗对急性心肌梗死患者心肌灌注和内皮功能的影响[J].中华危重 症医学杂志:电子版,2016,9(1):3-8.
[8] 许勇,陈小玲,冯仕勇,等.瑞替普酶溶栓治疗早期急性ST 段上抬性 心肌梗死及择期冠脉造影疗效分析[J].中西医结合心血管病电子杂 志,2015,3(29):80-81.
[9] 淡利军.尿激酶治疗对心肌梗死患者心肌耗氧量、肌酸磷酸激酶 和心电图变化的临床观察[J].中国循证心血管医学杂志,2016,8(1):100-102.
[10] 魏俊桃.尿激酶静脉溶栓治疗急性心肌梗死70 例临床观察[J].中 国实用医刊,2016,43(5):26-27.
[11] 孙金良.瑞替普酶溶栓治疗急性心肌梗死的疗效观察[J].中西医 结合心血管病电子杂志,2015,3(22):49-50.